**Table 1: Overall baseline characteristics**

| | Active treatment n= 40 (%) | Placebo n= 22 (%) | Total n= 62 (%) |
|---|---|---|---|
| **Median age (IQR range)** | 67.5(60 -71) | 63.6 (55–68) | 66.3 (56-71) |
| **Primary cancer site** | | | |
| **Prostate** | 22 (55) | 12 (55) | 34 (55) |
| **Cervix** | 8 (20) | 5 (23) | 13 (20) |
| **Endometrium** | 4 (10) | 2 (9) | 6 (10) |
| **Ovary** | 1 (2.5) | 0 | 1 (1.5) |
| **Vagina/vulva** | 0 | 1 (4) | 1 (1.5) |
| **Rectum** | 1 (2.5) | 0 | 1 (1.5) |
| **Anus** | 4 (10) | 2 (9) | 6 (10) |
| **Median time in months since completion of radiotherapy (IQR range)** | 36 (23 -58) | 42 (31 -57) | 39 (25 – 57) |
| **IBDQ score < 60** | 21 (52.5) | 12 (54.5) | 33 (53) |
| **IBDQ score >60** | 19 (47.5) | 10 (45.5) | 29 (47) |
| **Treated with RT alone** | 28 (70) | 12 (55) | 40 (65) |
| **Treated with combined Chemo and RT** | 12 (30) | 10 (45) | 22 (35) |

**Table 2: Treatment outcomes**

| | Active treatment n= 40 (%) | Placebo n= 22 (%) | Total n= 62 (%) |
|---|---|---|---|
| **Treatment status** | | | |
| **Never started treatment** | 2 (5) | 1 (5) | 3 (5) |
| **Treatment completed** | 28 (70) | 17 (77) | 45 (72.5) |
| **Treatment ended early** | 10 (25) | 4 (18) | 14 (22.5) |
| **Reason Treatment ended early** | | | |
| **Adverse event** | 4 (40) | 2 (50) | 6 (43) |
| **Patient choice** | 3 (30) | 1 (25) | 4 (28) |
| **Recurrence** | 1 (10) | 0 (0) | 1 (7) |
| **Other** | 1 (10) | 1 (25) | 2 (14) |
| **Unknown** | 1 (10) | 0 (0) | 1 (7) |

**Table 3: Levels of gamma tocotrienol (GT3) measured in the same individual in the placebo and the active treatment groups before study medication was dispensed and at 6 months.**

| Placebo group | | Active treatment group | |
|---|---|---|---|
| **Baseline GT3 levels** ng/ml | **6 month GT3 level** ng/ml | **Baseline GT3 levels** ng/ml | **6 month GT3 level** ng/ml |
| < 10 | < 10 | < 10 | N/A |
| < 10 | N/A | < 10 | < 50 |
| < 10 | < 50 | < 10* | 139 |
| < 10 | < 10 | < 10 | 548 |
| < 10 | < 50 | < 10* | 322 |
| < 10 | < 10 | < 10 | 107 |
| < 10 | < 10 | < 10 | 758 |
| < 10 | < 10 | < 10 | 804 |
| N/A | < 10 | < 10 | < 50 |
| < 10 | < 10 | < 10 | < 10 |
| < 10 | < 10 | < 10 | 52.3 |
| < 50 | < 50 | N/A | 520 |
| N/A | < 10 | < 10 | 1280 |
| < 10 | < 10 | < 10 | < 50 |
| N/A | < 10 | < 10 | 51.5 |
| < 10* | < 10 | < 10 | < 50 |
| < 10 | < 10 | < 10* | 147 |
| < 10* | < 10 | < 10 | < 10 |
| < 10 | < 10 | < 10 | N/A |
| < 50 | < 10 | < 10 | 544 |
| | | < 10 | 331 |
| | | < 10 | < 10 |
| | | < 10 | 101 |
| | | N/A | 117 |
| | | < 10 | 404 |
| | | < 50 | < 50 |
| | | < 10 | < 50 |
| | | < 10 | < 50 |
| | | < 10 | < 50 |
| | | < 10 | 237 |
| | | < 50 | 409 |
| | | < 10 | N/A |
| | | < 10 | 439 |
| | | < 10 | 461 |

**The assay used could not detect levels of GT3 below 10ng/ml and could not quantify the level of GT3 below 50ng/ml.**
*** indicate that no baseline sample was available however, instead a 24 month sample was used.**
**N/A indicated that no sample was available at this time point.**

**Table 4: Serious adverse events**

| | | Treatment group n=38<br><br>Patients Affected n= (%) | Placebo group n=21<br><br>Patients Affected n= (%) |
|---|---|---|---|
| **Gastrointestinal disorders** | Small bowel obstruction | 0 *(0)* | 1 *(5)* |
| | Large bowel obstruction | 0 *(0)* | 1 *(5)* |
| | Vomiting | 1 *(3)* | 1 *(5)* |
| **Infections** | Pneumonia | 0 *(0)* | 1 *(5)* |
| **Injury** | Fall | 1 *(3)* | 0 *(0)* |
| **New neoplasia** | Breast cancer | 1 *(3)* | 0 *(0)* |
| | Second primary | 1 *(3)* | 0 *(0)* |
| **Urinary disorders** | Haematuria | 1 *(3)* | 0 *(0)* |
| | Urinary tract infection | 0 *(0)* | 1 *(5)* |
| **Vascular disorders** | Transient ischaemic attack | 1* *(3)* | 0 *(0)* |

*This SAE was considered possibly related to pentoxifylline, all other SAEs considered unrelated to either drug.

Formatted: Font: Not Bold

Formatted: Font: Not Bold